Tatva Chintan Pharma Chem Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/r1676l6n0c7f57tz1wjt567c.pdf

Key Takeaways


Semiconductor: The Long-Game Bet Takes a Concrete Step

Chintan Shah: "And of course, as you know, any change in semiconductor is extremely difficult. So probably it's not an easy take off. It's going to be a tough time getting into the commercialization and acquiring business. But once we set our foot in into any commercial application, then I think it opens up doors for very large opportunity."

Electrolyte Salts & Battery Solutions: Supply Shock Masks Demand Visibility

Chintan Shah: "Unfortunately, we lost a couple of months due to unavailability of couple of key raw materials in this space. It just happened because of the war situation, which impacted our productivity."

Pharma & PASC Intermediates: The Near-Term Growth Engine


SDA & PTC: Structural Tailwinds from Regulation and Adoption


Operations & Strategy: Continuous Flow, Greenfield Capacity, and Margin Dynamics

Chintan Shah: "If Tatva can do, I don't believe someone else cannot do. So it's just about… if we say we are a very small company, if you see within the chemical segment then potentially, we are the smallest player within the segment… We can do, I'm sure, with given dedication or a given vision, any one of them can crack this."

Guidance & Commitments

CommitmentSpecificsTimeline
FY27 revenue growth25%–30% growth; Q1 run rate to be maintainedFY27
FY27 EBITDA margin20%–22%FY27
Pharma molecules revenue₹70–₹80 cr contribution from all pharma moleculesFY27
Electrolyte Salts revenue₹40–₹60 crFY27
Greenfield facility operationalSite operational; internally pushed for 18 monthsWithin 21 months
Greenfield peak revenue~₹300 cr at peak utilizationAt peak utilization
Semiconductor plant-scale trialsAt least 3–4 trials to demonstrate quality consistencyOver next 2 years
Semiconductor large-volume commercializationNot before Q4 of 2028Q4 2028 or later
Hybrid battery customer commercial supplyFull-scale commercialization expectedLate 2027
Long-term compounded growthAt least 20%–25% year-on-year, assuming Jolva commercializesOver next 4 years
Post-tax ROIC target20%–22%Not specified
Mature pipeline commercialization8–9 products expected to commercializeBefore 2028

Key Metrics

MetricQ1 FY27
Operating revenue₹167.1 cr, +43% YoY and +25% QoQ
EBITDA₹32.3 cr, +86% YoY and +15% QoQ
EBITDA margin19.3% (per an analyst's math); guidance maintained at 20–22% for FY27
Phase Transfer Catalysts revenue₹42.8 cr, +47% YoY and +38% QoQ
Structure Directing Agents revenue₹57.8 cr, +47% YoY and +10% QoQ
Pharma & Agro Intermediates and Specialty Chemicals revenue₹58.4 cr, +25% YoY and +63% QoQ
Electrolyte Salts revenue₹6.3 cr, +76% YoY and -52% QoQ
FY27 revenue growth guidance25–30%
FY27 EBITDA margin guidance20–22%
Electrolyte Salts FY27 revenue guidance₹40–60 cr
New pharma molecules FY27 revenue contribution expected₹70–80 cr
New greenfield capex approved~₹200 cr, groundbreaking 20 July 2026; peak revenue potential ~₹300 cr at 1.2–1.5x asset turnover
Semiconductor products pipeline5 products: 1 plant-scale qualified, 1 pilot-scale under evaluation, 3 in development
Mature pipeline products (ex-semiconductor)8–9 products expected to commercialize before 2028
Continuous flow chemistry products currently commercial2 products